300 related articles for article (PubMed ID: 29200160)
1. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Gomber S; Dabas A; Bagmar S; Madhu SV
J Pediatr Hematol Oncol; 2018 Jan; 40(1):56-59. PubMed ID: 29200160
[TBL] [Abstract][Full Text] [Related]
2. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
4. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
5. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
6. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy.
Platis O; Anagnostopoulos G; Farmaki K; Posantzis M; Gotsis E; Tolis G
Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():279-81. PubMed ID: 16462711
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Liang Y; Bajoria R; Jiang Y; Su H; Pan H; Xia N; Chatterjee R; Lai Y
Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with deferiprone and desferrioxamine.
Wonke B; Wright C; Hoffbrand AV
Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
14. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
Piga A; Gaglioti C; Fogliacco E; Tricta F
Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
[TBL] [Abstract][Full Text] [Related]
17. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Aydinok Y; Evans P; Manz CY; Porter JB
Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
[TBL] [Abstract][Full Text] [Related]
18. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
19. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V
Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
[TBL] [Abstract][Full Text] [Related]
20. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Peng CT; Chow KC; Chen JH; Chiang YP; Lin TY; Tsai CH
Eur J Haematol; 2003 Jun; 70(6):392-7. PubMed ID: 12756022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
